Drugmakers increasingly view Trump as a business risk in federal filings

Biotech firms have always faced a litany of business risks — from having drugs fail in clinical trials, to heavy competition to running out of money. Recently, many are adding one more to the list: the Trump Administration. Since Trump took office, biotech and pharma companies have repeatedly cited his administration — and in particular, uncertainty o ver what policies he will enact and how they will affect the industry — in the “risk factors” section of their annual and quarterly filings…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news